Results 221 to 230 of about 3,241,751 (271)
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Conflict of Interest Disclosure in Oncology: Preliminary Insights From the Global ONCOTRUST-1 Cross-Sectional Study. [PDF]
El Bairi K +18 more
europepmc +1 more source
The Structural Madness of Self-Verification: Conflict of Interest at the Heart of Science
Ryuhei ISHIBASHI
openalex +1 more source
Explaining the concepts and examples of conflict of interest and its management in the medical laboratory system of Iran: A scoping review. [PDF]
Dargahi H, Kooshkebaghi M, Isazadeh N.
europepmc +1 more source
Errors in Key Points, Abstract, Results, Table 2, and Conflict of Interest Disclosures.
europepmc +1 more source
Conflict of interest in biomedical publications
Nayak Barun
doaj

